The Role of Ki-67 and ctDNA as Prognostic or Predictive Markers in Breast Cancer
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.
Related Articles
Cilta-cel Shows High Responses for Lenalidomide-Refractory Myeloma in First Relapse
The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
Cranial Nerve Palsy Present Across CARTITUDE Trials in Multiple Myeloma
Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.
FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
Addressing the Growing Colorectal Cancer Incidence in Younger Populations
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.